Precision Medicine in the Prostate Cancer Care Pathway
Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Feb 18, 2021
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Precision Medicine in the Prostate Cancer Care Pathway," is studying a special genetic test designed for men who are at high risk for prostate cancer. The test looks at a man's DNA to identify specific genetic changes that might increase his chances of developing prostate cancer. By understanding these genetic risks, healthcare providers hope to improve how they screen for and treat prostate cancer in the future.
To participate in this study, men must either have been diagnosed with prostate cancer before age 70, have a specific type of advanced prostate cancer, or have a strong family history of the disease. Those without prostate cancer but with a significant family history may also be eligible. If you join the study, you can expect to provide a DNA sample for testing and receive information that could help guide your healthcare decisions. This trial is currently recruiting participants, and it's important to note that individuals with certain health conditions may not qualify.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- Affected cohort:
- • 1. Affected with PrCa \< 70 years or
- • 2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or
- • 3. Affected with PrCa and a family history defined as
- • 1. two or more cases in family with one case \< 70
- • 2. three or more cases any age (FDR or SDR)
- Unaffected cohort:
- Aged \>30 and with a family history defined as:
- • 1. FDR diagnosed \< 70
- • 2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years
- • 3. 3 or more cases at any age (on same side of family)
- Exclusion Criteria:
- • • WHO performance status 4
About Institute Of Cancer Research, United Kingdom
The Institute of Cancer Research (ICR) in the United Kingdom is a leading cancer research organization dedicated to understanding the biology of cancer and developing innovative therapeutic strategies. Renowned for its pioneering contributions to cancer treatment and prevention, the ICR conducts cutting-edge clinical trials that translate laboratory discoveries into effective clinical applications. Collaborating with a network of academic, clinical, and industry partners, the ICR is committed to advancing cancer research and improving patient outcomes through rigorous scientific inquiry and a patient-centered approach.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sutton, England, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials